If you have been reading about reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
9 January – Séamus Begley, 73, traditional musician and singer. 16 January Carrie Acheson, 88, politician, TD (1981–1982). Joe Martin, 91, footballer (Dundalk, League of Ireland XI). 18 January – John L. Murray, 79, jurist, chief justice (2004–2011), judge of the Supreme Court (1999–2015) and the ECJ (1992–1999). 19 January Bertie Cunningham, 83, Gaelic footballer (Ballivor, Meath senior team). Peter Thomas, 78, footballer (Waterford, Galway United, national team). Born in England. 20 January – Pierce Higgins, 45, hurler (Tooreen, Ballyhaunis, Mayo senior team), motor neuron disease. 21 January – Micheál Mac Gréil, 91, Jesuit priest, sociologist and writer. 30 January – Eddie Spence, 97, Gaelic footballer (Belfast O'Connell's, Antrim senior team). Born in Northern Ireland. 31 January – Donie Hanlon, 85, Gaelic footballer (Gracefield, Offaly senior team).
== Research == Fischer and Jandera studied the effect of changing the concentration of methanol on CMC values for three commonly used surfactants. Two cationic, hexadecyltrimethylammonium bromide (CTAB), and N-(a-carbethoxypentadecyl) trimethylammonium bromide (Septonex), and one anionic surfactant, sodium dodecyl sulphate (SDS) were chosen for the experiment. Generally speaking, the CMC increased as the concentration of methanol increased. It was then concluded that the distribution of the surfactant between the bulk mobile phase and the micellar phase shifts toward the bulk as the methanol concentration increases. For CTAB, the rise in CMC is greatest from 0–10% methanol, and is nearly constant from 10–20%. Above 20% methanol, the micelles disaggregate and do not exist. For SDS, the CMC values remain unaffected below 10% methanol, but begin to increase as the methanol concentration is further increased. Disaggregation occurs above 30% methanol. Finally, for Septonex, only a slight increase in CMC is observed up to 20%, with disaggregation occurring above 25%. As has been asserted, the mobile phase in MLC consists of micelles in an aqueous solvent, usually with a small amount of organic modifier added to complete the mobile phase. A typical reverse phase alkyl-bonded stationary phase is used. The first discussion of the thermodynamics involved in the retention mechanism was published by Armstrong and Nome in 1981. In MLC, there are three partition coefficients which must be taken into account.
The Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research is awarded by Brandeis University. It was established in 1971 "as an expression of the conviction that educational institutions have an important role to play in the encouragement and development of basic science as it applies to medicine". Medals are presented annually at Brandeis University on the basis of recommendations of a panel of scientists selected by the Rosenstiel Basic Medical Sciences Research Center. Awards are given to scientists for recent discoveries of "particular originality" and "importance to basic medical research". A $30,000 prize and a medallion accompanies each award. The Rosenstiel Basic Medical Sciences Research Center, named after Lewis Solon Rosenstiel, was established in 1968, carrying out research in basic medical science.
Sources: en.wikipedia.org
= Reaction volume The SI unit is the katal, 1 katal = 1 mol s−1 (mole per second), but this is an excessively large unit. A more practical and commonly used value is enzyme unit (U) = 1 μmol min−1 (micromole per minute). 1 U corresponds to 16.67 nanokatals. Enzyme activity as given in katal generally refers to that of the assumed natural target substrate of the enzyme. Enzyme activity can also be given as that of certain standardized substrates, such as gelatin, then measured in gelatin digesting units (GDU), or milk proteins, then measured in milk clotting units (MCU). The units GDU and MCU are based on how fast one gram of the enzyme will digest gelatin or milk proteins, respectively. 1 GDU approximately equals 1.5 MCU. An increased amount of substrate will increase the rate of reaction with enzymes, however once past a certain point, the rate of reaction will level out because the amount of active sites available has stayed constant.
More research is needed to determine the precise effects of HMB on muscle strength and function in various populations. In severe cases of muscular atrophy, the use of an anabolic steroid such as methandrostenolone may be administered to patients as a potential treatment although use is limited by side effects. A novel class of drugs, called selective androgen receptor modulators, is being investigated with promising results. They would have fewer side effects, while still promoting muscle and bone tissue growth and regeneration. These effects have yet to be confirmed in larger clinical trials.
=== Neural circuit mechanism with PGE2 action === PGE2 release comes from the arachidonic acid pathway. This pathway (as it relates to fever), is mediated by the enzymes phospholipase A2 (PLA2), cyclooxygenase-2 (COX-2), and prostaglandin E2 synthase. These enzymes ultimately mediate the synthesis and release of PGE2. PGE2 is the ultimate mediator of the febrile response. The setpoint temperature of the body will remain elevated until PGE2 is no longer present. PGE2 acts on neurons in the preoptic area (POA) through the prostaglandin E receptor 3 (EP3). EP3-expressing neurons in the POA innervate the dorsomedial hypothalamus (DMH), the rostral raphe pallidus nucleus in the medulla oblongata (rRPa), and the paraventricular nucleus (PVN) of the hypothalamus. Under normal conditions, EP3-expressing neurons in the POA are important thermoregulatory neurons, which provide continuous inhibitory signals with the transmitter GABA to control sympathetic output neurons in the DMH and rRPa, thereby performing bidirectional regulation of basal body temperature. During infection, PGE2 produced in the brain inhibits the activity of EP3-expressing neurons in the POA to attenuate the inhibition of sympathetic output, and thereby activates the sympathetic output system, which evokes non-shivering thermogenesis to produce body heat and skin vasoconstriction to decrease heat loss from the body surface, leading to fever.
== Research == The exact mechanism for this protein is currently not known, but efforts continue to isolate activated protein C mutants that lack anticoagulant properties for potential therapeutic use.
Sources: en.wikipedia.org
== Function == This "classical" PTH receptor is expressed in high levels in bone and kidney and regulates calcium ion homeostasis through activation of adenylate cyclase and phospholipase C. In bone, it is expressed on the surface of osteoblasts. When the receptor is activated through PTH binding, osteoblasts express RANKL (Receptor Activator of Nuclear Factor kB Ligand), which binds to RANK (Receptor Activator of Nuclear Factor kB) on osteoclasts. This turns on osteoclasts to ultimately increase the resorption rate.
Malaya, officially the Federation of Malaya, was a country in Southeast Asia from 1948 to 1963. It succeeded the Malayan Union and, before that, British Malaya. It comprised eleven states – nine Malay states and two of the Straits Settlements, Penang and Malacca. It was established on the 1st of February 1948. Initially a self-governing colony of the United Kingdom, Malaya became fully sovereign on 31 August 1957, and on 16 September 1963, the federation was superseded by Malaysia when it united with Singapore, North Borneo (Sabah) and Sarawak. Singapore left on 9 August 1965, leaving the original states of Malaya along with Sarawak and Sabah – now collectively known as East Malaysia – to form modern-day Malaysia, while the former Federation of Malaya is now referred to as Peninsular Malaysia or West Malaysia.
== Biotechnology research == Hamer invented the first method for introducing new genes into animal cells using SV40 vectors while a graduate student at Harvard Medical School. This approach was used to produce a variety of biomedical products including human growth hormone and a vaccine for Hepatitis B, resulting in 4 US patents. At NIH, Hamerʻs lab initially focused on the metallothionein gene system. They elucidated the mechanism of induction of yeast metallothionein by copper ions, one of the first eukaryotic gene regulatory systems to be understood at the molecular level and a useful method for regulating therapeutic protein production.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.